Trial Search Results

Characterization of Treatment Responses in Lymphedema

This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of clinical responses (changes in limb volume and skin thickness) with changes in the inflammasome will help to define the molecular substrate of treatment response.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Ketoprofen


Inclusion Criteria:

   - Participants with a history of acquired lymphedema

   - Stage 1, 2, or 3

   - 18-75 years

   - Clinical use of ketoprofen for lymphedema

Exclusion Criteria:

   - Active cancer, infection, bleeding tendency, inflammatory disease and/or taking
   anti-inflammatory or anti-leukotriene medication will be excluded.

   - Pregnant or lactating females

   - Inability to take ketoprofen (contra-indicated, e.g patients with known CV, GI, renal,
   hepatic disease).

   - Other severe acute or chronic medical or psychiatric condition or laboratory
   abnormality that may increase the risk associated with study participation, may
   interfere with interpretation of study results, and in the judgement of the
   investigator, would make the participation inappropriate for entry into this study.

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Leslie Roche, RN